Condition: Glioblastoma · Vaccination · Sponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Single arm, monocentric trial to assess the safety and the progression-free survival related to the combined treatment of dendritic cell vaccine loaded with autologous tumor homogenate and temozolomide in patients operated for glioblastoma and then treated with standard radiochemotherapy (according to Stupp regimen).
This description comes directly from the study's public registry record.
Oriana Nanni, DR · +39 0543739266 · oriana.nanni@irst.emr.it
Anna Miserocchi, DR · cc.ubsc@irst.emr.it
Always discuss trial participation with your own doctor first.
| Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) | Meldola, FC, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04523688